



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

4

## Complete if Known

Application Number	09/893,348
Filing Date	October 31, 2001
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	B. Bunner
Attorney Docket Number	EIS-SCHWARTZ=2A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BBB	BS	5,250,414	A	Schwab et al	10-05-1993
	BT	5,684,133	A	Schwab et al	11-04-1997
	BU	5,114,721	A	Cohen et al	05-19-1992
	BV	5,633,426	A	Namikawa et al	05-27-1997
	BW	5,858,364	A	Weiner et al	01-12-1999
BBB	BX	6,319,892	B1	Gold et al	11-20-2001

RECEIVED

JAN 16 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number	Kind Code <sup>5</sup> (if known)			
BBB	BY	WO	96/16085	A1	Neurocrine Biosciences Inc. & Stanford Univ Medical Center	05-30-1996	—
	BZ	WO	93/00427	A2	Erziehungsdirektion Cant. Zurich	01-07-1993	—
	CA	WO	00/31235	A1/3	Schwab et al	06-02-2000	—
	CB	WO	00/60083	A1	Chiron Corporation	10-12-2000	—
BBB	CC	WO	01/36631	A1	Smithkline Beecham PLC	05-25-2001	—

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
BBB	CD	BECKER et al, "Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia", <i>Proc Natl Acad Sci USA</i> 94(20):10873-10878 (1997)					
	CE	BERKOW et al (Eds), <i>The Merck Manual of Diagnosis and Therapy</i> 16 <sup>th</sup> Ed., Merck Research Laboratories, Rahway, NJ, pp. 110, 111, 412, 413, 1452-1459, 1488-1490, 1510, 1511, and 1518-1523 (1992)					
	CF	BRADBURY et al, "NT-3, but not BDNF, prevents atrophy and death of axotomized spinal cord projection neurons", <i>Eur J Neurosci</i> ;10(10):3058-3068 (1998)					
BBB	CG	BROD et al, "Autologous T-T Cell Activation Mediated by Cell Adhesion Molecules", <i>FASEB J</i> 3(3):A514 (1989)					

Examiner Signature	Budget E. Bunner	Date Considered	9/15/03
--------------------	------------------	-----------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

RECEIVED



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 4

Complete if Known

Application Number	09/893,348	JAN 16
Filing Date	October 31, 2001	2003
First Named Inventor	Michal EISENBACH-SCHWARTZ	TECH CENTER 1600/2900
Group Art Unit	1647	
Examiner Name	B. Bunner	
Attorney Docket Number	EIS-SCHWARTZ=2A	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
BB	CH	COHEN et al, "Autoimmune maintenance and neuroprotection of the central nervous system", <u>J Neuroimmuno</u> ; 100(1-2):111-114 (1999)	-
	CI	ENOCH et al, "Different functional changes recorded in open angle glaucoma and anterior ischemic optic neuropathy", <u>Doc Ophthalmol</u> 50(1):169-184 (1980)	-
	CJ	GEORGE et al, "Axotomy-induced axonal degeneration is mediated by calcium influx through ion-specific channels", <u>J Neurosci</u> 15(10):6445-6452 (1995)	-
	CK	HAUBEN et al, "Autoimmune T cells as potential neuroprotective therapy for spinal cord injury", <u>Lancet</u> 355(9200):286-287 (2000)	-
	CL	HAUBEN et al, "Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion", <u>J Neurosci</u> 20(17):6421-6430 (2000)	-
	CM	HAY RJ, "Human cells and cell cultures: availability, authentication and future prospects", <u>Hum Cell</u> 9(3):143-152 (1996)	-
	CN	JACKOWSKI A, "Neural injury repair: hope for the future as barriers to effective CNS regeneration become clearer", <u>Br J Neurosurg</u> 9(3):303-317 (1995)	-
	CO	KANDEL et al (Eds.), <u>Principles of Neural Science</u> , Elsevier Science Publishing Co., Inc. (New York, NY), pp. 977-982	-
	CP	LI et al, "β-Endorphin omission analogs: dissociation of immunoreactivity from other biological activities", <u>Proc Natl Acad Sci USA</u> 77(6):3211-3214 (1980)	-
	CQ	LIUZZI et al, "Peripheral nerve regeneration", <u>Neurosurg Clin N Am</u> 2(1):31-42 (1991)	-
	CR	LOHSE et al, "Control of Experimental Autoimmune Encephalomyelitis by T Cells Responding to Activated T Cells", <u>Science</u> 244:820-822 (1989)	-
BB	CS	LOHSE et al, "Inhibition of the mixed lymphocyte reaction by T cell vaccination", <u>Eur J Immunol</u> 20:2521-2524 (1990)	-

Examiner Signature

*Bridget E. Bunner*

Date Considered

9/15/03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

JAN 15 2003



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

4

Complete if Known

RECEIVED

Application Number	09/893,348
Filing Date	October 31, 2001
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	B. Bunner
Attorney Docket Number	EIS-SCHWARTZ=2A

JAN 16 2003

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
<i>BEB</i>	CT	LOHSE et al, "Induction of the anti-ergotypic response", <u>International Immunology</u> 4(5):533-539 (1993)
	CU	MOALEM et al, "Autoimmune T cells retard the loss of function in injured rat optic nerves", <u>J Neuroimmunol</u> 106(1-2):189-197 (2000)
	CV	MORRIS et al, "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease", <u>Neurology</u> 39(9) 1159-1165 (1989)
	CW	PAN et al, "Tumor necrosis factor-alpha: a neuromodulator in the CNS", <u>Neurosci Biobehav Rev</u> 21(5):603-613 (1997)
	CX	PLATA SALAMAN C, "Epidermal growth factor and the nervous system", <u>Peptides</u> 12(3):653-663 (1991)
	CY	PETROVICH et al, "Pentoxifylline suppression of TNF- $\alpha$ mediated axonal degeneration in the rabbit optic nerve", <u>Neurol Res</u> 19(5):551-554 (1997)
	CZ	POSER CM, "The role of trauma in the pathogenesis of multiple sclerosis a review", <u>Clin Neurol Neurosurg</u> 96(2):103-110 (1994)
	DA	SKOLNICK et al, "From genes to protein structure and function: novel applications of computational approaches in the genomic era", <u>Trends Biotechnol</u> 18(1):34-39 (2000)
	DB	TANABE et al, "Diversity and pattern in the developing spinal cord", <u>Science</u> 274(5290):1115-1123 (1996)
	DC	WANG et al, "Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy", <u>J Neuropathol Exp Neurol</u> 59(7):599-606 (2000)
<i>BEB</i>	DD	YÜCEL et al, "Histomorphometric analysis of optic nerve changes in experimental glaucoma", <u>J Glaucoma</u> 8(1):38-45 (1999)
<i>BEB</i>	DE	YUEN et al, "Immunoregulatory CD8 $^{+}$ Cells Recognize Antigen-Activated CD4 $^{+}$ Cells in Myasthenia Gravis Patients and in Healthy Controls", <u>J Immunol</u> 154(3):1508-1520 (1995)

Examiner Signature


*Bridget E. Bunner*

Date Considered

9/15/03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

JAN 15 2003

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Shee

4

T

**Complete if Known**

Application Number	09/893,348
Filing Date	October 31, 2001
First Named Inventor	Michal EISENBACK-SCHWARTZ
Group Art Unit	1647
Examiner Name	B. Bunner
Attorney Docket Number	EIS-SCHWARTZ=2A

#### **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

RECEIVED

JAN 16 2003

TECH CENTER 1600/2900

Examiner Signature	Bridget E. Dunner	Date Considered	9/15/03
-----------------------	-------------------	--------------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.